This inventor holds 1 USPTO granted patent and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Daiichi Asubio Pharma Co., Ltd.. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Tomohiro Makino: Innovator in Peptide Production
Introduction
Tomohiro Makino is a distinguished inventor based in Tatebayashi, Japan. He has made significant contributions to the field of biochemistry, particularly in the production of modified peptides. His innovative approach has the potential to enhance the quality and effectiveness of peptide-based therapies.
Latest Patents
Makino holds a patent for a method for producing a modified peptide. This invention involves a process that chemically produces a peptide fragment containing an amino acid residue with a modified side chain using a weak acid-cleavable resin. Additionally, it includes producing another peptide fragment without the modified side chain through genetic recombination or enzymatic methods. The resulting two peptide fragments can be condensed to yield a peptide or protein with modifications such as acylation, glycosylation, and phosphorylation, achieved effectively and with high quality. He has 1 patent to his name.
Career Highlights
Tomohiro Makino is associated with Daiichi Asubio Pharma Co., Ltd., where he continues to advance his research and development efforts. His work is pivotal in the pharmaceutical industry, particularly in the development of therapeutic peptides.
Collaborations
Makino collaborates with notable colleagues, including Yoshiharu Minamitake and Masaru Matsumoto. Their combined expertise contributes to the innovative projects at Daiichi Asubio Pharma Co., Ltd.
Conclusion
Tomohiro Makino's contributions to peptide production represent a significant advancement in biochemistry. His innovative methods and collaborations are paving the way for future developments in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile